NYSE - Delayed Quote • USD
ResMed Inc. (RMD)
At close: April 24 at 4:00 PM EDT
After hours: April 24 at 6:58 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 10 | 9 | 12 | 12 |
| Avg. Estimate | 1.91 | 1.96 | 7.4 | 8.19 |
| Low Estimate | 1.81 | 1.86 | 7.24 | 7.92 |
| High Estimate | 1.99 | 2.09 | 7.63 | 8.85 |
| Year Ago EPS | 1.68 | 1.6 | 6.44 | 7.4 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 12 | 11 | 17 | 17 |
| Avg. Estimate | 1.17B | 1.19B | 4.63B | 4.95B |
| Low Estimate | 1.14B | 1.17B | 4.59B | 4.81B |
| High Estimate | 1.19B | 1.23B | 4.68B | 5.05B |
| Year Ago Sales | -- | 1.12B | 4.22B | 4.63B |
| Sales Growth (year/est) | -- | 6.40% | 9.70% | 6.80% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 1.59 | 1.69 | 1.62 | 1.8 |
| EPS Actual | 1.68 | 1.6 | 1.64 | 1.88 |
| Difference | 0.09 | -0.09 | 0.02 | 0.08 |
| Surprise % | 5.70% | -5.30% | 1.20% | 4.40% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 1.91 | 1.96 | 7.4 | 8.19 |
| 7 Days Ago | 1.9 | 1.96 | 7.41 | 8.18 |
| 30 Days Ago | 1.9 | 1.96 | 7.45 | 8.13 |
| 60 Days Ago | 1.9 | 1.96 | 7.45 | 8.13 |
| 90 Days Ago | 1.85 | 1.91 | 7.22 | 7.97 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | -- | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | RMD | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 13.70% | -- | -- | 1.50% |
| Next Qtr. | 22.50% | -- | -- | 11.40% |
| Current Year | 14.90% | -- | -- | 5.20% |
| Next Year | 10.70% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 13.00% | -- | -- | 11.09% |
| Past 5 Years (per annum) | 13.05% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Needham: Buy to Buy | 4/1/2024 |
| Maintains | Mizuho: Buy to Buy | 3/27/2024 |
| Initiated | Keybanc: Overweight | 2/6/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 1/30/2024 |
| Maintains | Mizuho: Buy to Buy | 1/30/2024 |
| Maintains | Mizuho: Buy to Buy | 1/26/2024 |
Related Tickers
RGEN Repligen Corporation
167.86
-2.00%
WST West Pharmaceutical Services, Inc.
385.73
-1.15%
ISRG Intuitive Surgical, Inc.
375.01
-0.55%
BDX Becton, Dickinson and Company
233.83
-0.23%
BAX Baxter International Inc.
40.93
-0.22%
HOLX Hologic, Inc.
76.71
-0.62%
COO The Cooper Companies, Inc.
90.20
-1.61%
ALC Alcon Inc.
79.57
-1.47%
NVST Envista Holdings Corporation
20.28
+0.30%
ICUI ICU Medical, Inc.
96.72
-1.06%